Who benefits from phase I studies?
Ann Oncol
.
1990;1(3):164-5.
doi: 10.1093/oxfordjournals.annonc.a057712.
Authors
C Sessa
,
F Cavalli
PMID:
2261361
DOI:
10.1093/oxfordjournals.annonc.a057712
No abstract available
Publication types
Editorial
MeSH terms
Drug Evaluation* / methods
Ethics, Medical*
Humans
Neoplasms / drug therapy*